The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy
Open accessAbstract
Alzheimer's disease is characterized by amyloid plaques, neurofibrillary tangles, glial activation, and neurodegeneration. In mouse models, inflammatory activation of microglia accelerates tau pathology. The chemokine fractalkine serves as an endogenous neuronal modulator to quell microglial activation. Experiments with fractalkine receptor null mice suggest that fractalkine signaling diminishes tau pathology, but exacerbates amyloid pathology. Consistent with this outcome, we report here that soluble fractalkine overexpression using adeno-associated viral vectors significantly reduced tau pathology in the rTg4510 mouse model of tau deposition. Furthermore, this treatment reduced microglial activation and appeared to prevent neurodegeneration normally found in this model. However, in contrast to studies with fractalkine receptor null mice, parallel studies in an APP/PS1 model found no effect of increased fractalkine signaling on amyloid deposition. These data argue that agonism at fractalkine receptors might be an excellent target for therapeutic intervention in tauopathies, including those associated with amyloid deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“tau pathology was reduced by inhibiting microglial activation via overexpression of CX3CL1, a chemokine released by neurons that binds to microglial-expressed CX3CR1 [240] or by administration of anti-inflammatory drugs [113]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [240]
In the citing paper
“Microglia first sense and clear tau in an attempt to protect from tau toxicity, but dysregulation of microglial sensing and housekeeping pathways, such as the Cx3cr1 and Trem2 pathways, lead to dysregulation of the host-defense pathway, resulting in a neuroinflammatory response gone awry, causing neuronal damage and loss55–57.”
From Microglia in neurodegeneration (2018) · cites this paper as [56]
In the citing paper
“overexpressing a soluble form of CX3CL1, the ligand for CX3CR1, reduces microglial cell activation and tau pathology in rTg4510 mice [G]64.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [64]
In the citing paper
“Similarly, overexpression of soluble CX3CL1 reduces microglial activation and neuronal loss in rTg4510 mice64.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Self-citationGlutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531
Imai, T., Hieshima, K., Haskell, C. A., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T. J., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80438-9 · Cited by 1,472
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Self-citationWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Harrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K., Streit, W. J., Salafranca, M. N., Adhikari, S., Thompson, D. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10896 · Cited by 1,176
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Hundhausen, C., Misztela, D., Berkhout, T. A., BROADWAY, N. M., Säftig, P., Reiß, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V. B., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3775 · Cited by 731
Garton, K. J., Gough, P. J., Blobel, C., Murphy, G., Greaves, D. R., Dempsey, P. J., & Raines, E. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106434200 · Cited by 653
Regulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript CX3CR1−/− mice with a human tau line resulted in an increase in tau pathology (Bhaskar et al., 2010).”
BackgroundProduction and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Philipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 564
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease
Fuhrmann, M., Bittner, T., Jung, C. K. E., Burgold, S., Page, R. M., Mitteregger, G., Haass, C., LaFerla, F. M., Kretzschmar, H., & Herms, J. (2010) · Nature Neuroscience · doi:10.1038/nn.2511 · Cited by 562
Lee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., & Lamb, B. T. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100265 · Cited by 522 · cited 4×
“We have previously shown that sFKN reduces microglial activation (Morganti et al., 2012), therefore, in this study we examined the level of CD45 positive staining in our 2 animal groups, a microglial marker we have found previously elevated in Tg4510 mice (Lee et al., 2010a).”
BackgroundMethodInfluentialA randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
The inflammatory macrophage: a story of Jekyll and Hyde
Duffield, J. S. (2002) · Clinical Science · doi:10.1042/cs1040027 · Cited by 445
Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31450 · Cited by 433
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402 · cited 1×
“This observation has led a series of failed attempts to treat AD with immunosuppressive agents such as steroids (Aisen et al., 2000) or NSAIDs (Aisen et al., 2003; Thal et al., 2005).”
BackgroundMicroglial senescence: does the brain's immune system have an expiration date?
Streit, W. J. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.001 · Cited by 397
A randomized controlled trial of prednisone in Alzheimer’s disease
Koch, H. J., & Szecsey, A. (2000) · Neurology · doi:10.1212/wnl.55.7.1067 · Cited by 381
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Chapman, G. A., Moores, K., Harrison, D. C., Campbell, C. A., Stewart, B. R., & Strijbos, P. J. L. M. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-15-j0004.2000 · Cited by 350
Arendash, G. W., King, D. L., Gordon, M. N., Morgan, D., Hatcher, J. M., Hope, C. E., & Diamond, D. M. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03186-3 · Cited by 349
Self-citationMicroglia and Alzheimer's disease pathogenesis
Streit, W. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20093 · Cited by 335
In vivo structure/function and expression analysis of the CX3C chemokine fractalkine
Kim, K.-W., Vallon-Eberhard, A., Zigmond, E., Farache, J., Shezen, E., Shakhar, G., Ludwig, A., Lira, S. A., & Jung, S. (2011) · Blood · doi:10.1182/blood-2011-04-348946 · Cited by 299
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice
Lee, D. C., Rizer, J., Selenica, M.-L. B., Reid, P., Kraft, C., Johnson, A., Blair, L., Gordon, M. N., Dickey, C. A., & Morgan, D. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-56 · Cited by 293
Self-citationCarroll, J. C., Iba, M., Bangasser, D. A., Valentino, R. J., James, M. J., Brunden, K. R., Lee, V. M. ‐., & Trojanowski, J. Q. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3836-11.2011 · Cited by 265
Alamed, J., Wilcock, D. M., Diamond, D. M., Gordon, M. N., & Morgan, D. (2006) · Nature Protocols · doi:10.1038/nprot.2006.275 · Cited by 256
Self-citationTime Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse
Gordon, M. N., Holcomb, L. A., Jantzen, P. T., DiCarlo, G., Wilcock, D., Boyett, K. W., Connor, K., Melachrino, J., O'Callaghan, J. P., & Morgan, D. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7754 · Cited by 247
Self-citationCX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease
Pabon, M. M., Bachstetter, A. D., Hudson, C. E., Gemma, C., & Bickford, P. C. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-9 · Cited by 241
Self-citationvan Rossum, D., & Hanisch, U. (2004) · Metabolic Brain Disease · doi:10.1023/b:mebr.0000043984.73063.d8 · Cited by 239
The inflammatory macrophage: a story of Jekyll and Hyde
Duffield, J. S. (2003) · Clinical Science · doi:10.1042/cs20020240 · Cited by 238
Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years
McGeer, P. L., Rogers, J., & McGeer, E. G. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s330 · Cited by 222
Lyons, A., Lynch, A. M., Downer, E. J., Hanley, R., O’Sullivan, J. B., Smith, A., & Lynch, M. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06253.x · Cited by 202
Klein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., & Henning, P. P. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300331 · Cited by 196
Morgan, D., Gordon, M. N., Tan, J., Wilcock, D. M., & Rojiani, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000178444.33972.e0 · Cited by 176
Self-citationTransmembrane chemokines: Versatile ‘special agents’ in vascular inflammation
Weber, C., & Ludwig, A. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-01-0035 · Cited by 175
Neuroimmunomodulation in the Pathogenesis of Alzheimer’s Disease
Morales, I., Farías, G., & Maccioni, R. B. (2010) · Neuroimmunomodulation · doi:10.1159/000258724 · Cited by 162
Herber, D. L., Mercer, M., Roth, L. M., Symmonds, K., Maloney, J. L., Wilson, N., Freeman, M. J., Morgan, D., & Gordon, M. N. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9069-z · Cited by 143
Self-citationMorganti, J. M., Nash, K. R., Grimmig, B. A., Ranjit, S., Small, B. J., Bickford, P. C., & Gemma, C. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0539-12.2012 · Cited by 141
Self-citationCarty, N., Lee, D. C., Dickey, C. A., Ceballos‐Diaz, C., Jansen‐West, K. R., Golde, T. E., Gordon, M. N., Morgan, D., & Nash, K. R. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.10.010 · Cited by 88
Self-citationDickey, C. A., Kraft, C., Jinwal, U. K., Koren, J., Johnson, A. G., Anderson, L. C., Lebson, L. A., Lee, D. C., Dickson, D. W., de Silva, R., et al. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080764 · Cited by 86
Self-citationShan, S., Hong-Min, T., Yi, F., Jun-Peng, G., Yue, F. L., Yan-hong, T., Yun-ke, Y., Li, W., Wang, X., Ma, J., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.004 · Cited by 82
Membrane‐bound form of fractalkine induces IFN‐γ production by NK cells
Yoneda, O., Imai, T., Nishimura, M., Miyaji, M., Mimori, T., Okazaki, T., Domae, N., Fujimoto, H., Minami, Y., Kono, T., et al. (2002) · European Journal of Immunology · doi:10.1002/immu.200390007 · Cited by 61
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Zujovic (2000) · doi:10.1002/(sici)1098-1136(20000215)29:4
Cited by
Sorted by citations
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight
Shi, Y., & Holtzman, D. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0051-1 · Cited by 595
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348
Metadata
- Authors
- Nash, K. R., Lee, D. C., Hunt, J. B., Morganti, J. M., Selenica, M.-L., Moran, P., Reid, P., Brownlow, M., Guang-Yu Yang, C., Savalia, M., Gemma, C., Bickford, P. C., Gordon, M. N., & Morgan, D.
- Affiliations
- University of South Florida (US)
- University of California, San Francisco (US)
- University of Washington (US)
- Corresponding author
- Nash, Kevin R.
- ORCID
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 34
- Issue
- 6
- Pages
- 1540-1548
- ISSN
- 0197-4580 (ISSN-L)
- PMC
- PMC8970215
- OpenAlex
- W2144997087
- Cited by
- 108
- References
- 50
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 10 · 2023: 8 · 2022: 5 · 2021: 8 · 2020: 8 · 2019: 11 · 2018: 8 · 2017: 7 · 2016: 9 · 2015: 10 · 2014: 9 · 2013: 7
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH/NIA (R01 AG025509, NIH NS76308, NIH AG15470)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- fractalkine, tau pathology, tauopathy, Alzheimer's disease, microglial activation, neuroinflammation, adeno-associated virus vectors, amyloid deposition, APP/PS1 mice, neurodegeneration, chemokines
- MeSH terms
- Animals, Disease Models, Animal, Gene Expression Regulation, Mice, Transgenic, tau Proteins, Tauopathies, Mice, Chemokine CX3CL1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
